Alemtuzumab in relapsed immune severe aplastic anemia: Long‐term results of a phase II study is a research paper published in American Journal of Hematology (2023). On theSindex it has a DataRank of 0.490. It has been cited 8 times, with 8 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.330
From this paper's citation signal
Citation Network Contribution
0.160
From 5 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 8 citers.
Doris Duke Charitable Foundation
Grant: 2014194
Intramural NIH HHS
Grant: Z99 HL999999
National Heart, Lung, and Blood Institute
American Association for Dental, Oral, and Craniofacial Research
Genentech
FWCI
1.47
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals